拉米夫定治疗慢性乙型肝炎生存质量评价被引量：39

Evaluation of health related quality of life with treatment of lamivudine in chronic hepatitis B patients.

导出

摘要目的　评价拉米夫定治疗慢性乙型肝炎生存质量的改善状况。方法　分别于拉米夫定治疗前、治疗半年、1年采用SF 3 6量表测定 2 44例病人的生存质量评分。结果　与治疗前相比 ,拉米夫定治疗半年及 1年后在躯体角色RP( 9.6)、社会功能SF( 8.2 )、情绪角色RE( 11.8)和活力VT( 6.2 ) 4个领域得分有显著提高 (P <0 .0 5 ) ,主要集中在心理状态评分MCS( 3 .6)。结论　拉米夫定治疗慢性乙型肝炎病人能有效改善病人生存质量。 Objective To evaluate the quality of life (QOL) improvement in patients infected with chronic hepatitis B (CHB) following treatment with lamivudine (Suzhou manufactured/100mg for 52 weeks). Methods 244 patients randomly selected from lamivudine phase Ⅳ clinical trials completed the SF-36 assessments at baseline, 26 weeks and 52 weeks. Results Patients with chronic hepatitis B on lamivudine showed an improvement in quality of life in several domains such as role physical (RP 9.6), social function (SF 8.2) , role emotional (RE 11.8), vitality (VT 6.2) over 6 and 12 months compared to baseline especially concentrated in mean mental components (MCS 3.6).Conclusion Patients with chronic hepatitis B have significant improvement in quality of life after treatment with lamivudine.

作者姚光弼 Alison T M 黄瑛籍纳新杨莉

机构地区上海市静安区中心医院葛兰素史克中国投资有限公司复旦大学公共卫生学院卫生经济教研室

出处《肝脏》 2003年第4期3-5,68,共4页 Chinese Hepatology

关键词拉米夫定药物治疗慢性乙型肝炎生存质量质量评价 Lamivudine Chronic hepatitis B SF-36 Qality of life

分类号 R512.6 [医药卫生—内科学]

引文网络
相关文献

参考文献16

1Grosheide P, Van Damme P. Prevention and control of hepatitis B in the community. Communicable Diseases Series, No. 1 Antwerp, Belgium: Viral Hepatitis Prevention Board Secretariat; 1996.
2Lok ASF, Van Leeuwen DJ, Thomsa HC, et al. Psychosocial impact of chronic infection with hepatitis B virus on british patients. Genitourin Med, 1985,61:279-282.
3Deyo RA. The quality of life, research and care. Ann Intern Med,199 1, 114: 695-696.
4Anonymous. Quality of Life. Lancet 1991,338:350-351.
5McClellan WM, Anson C, Birkeli K, et al. Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease. J Clin Epidemiol, 1991,44:83-89.
6Ganz PA, Lee J J, Siau J. Quality of life assessment: an independent prognostic variable for survival in lung cancer. Cancer 1991,67:3131-3135.
7Nissinen A, Wiklund I, Lahti T, et al. Anti-anginal therapy and quality of life. A comparison of the effects of transdermal nitroglycerin and long-acting oral nitrates. J Clin Epidemiol, 1991,44:989-997.
8Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med, 1986,314: 1657-1664.
9Lenderking WR, Gelber RD, Cotton DJ, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic HIV infection. N Engl J Med, 1994,330:738-743.
10Watchel T, Piette J, Mor V, et al. Quality of life in persons with HIV infection: measurement by the medical outcomes study instrument. Ann Intern Med, 1992,116:129-137.